The global non-small cell lung cancer treatment market size attained a value of about USD 17.62 billion in 2022. The market is likely to grow at a rate of 10.00% during the forecast period of 2023-2031 to reach a value of nearly USD 41.97 billion by 2031. The growth of the market can be attributed to the growing demand for diagnostics and therapeutics.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer. There is an abnormal growth of cancerous cells in the lung tissues. This cancer is coined as “non-small” due to the presence of larger abnormal cells, in comparison to small cell lung cancer. The three types of non-small cell lung cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The signs and symptoms of non-small cell lung cancer consist of cough, shortness of breath, chest pain, hoarseness, wheezing, loss of appetite, and difficulty in swallowing and breathing.
The exact cause of non-small cell lung cancer is unknown, but the disease is set to be triggered by several risk factors, including smoking, air pollution, and exposure to certain metals, mineral dust, asbestos, radon, and harmful radiations. This type of cancer can also occur because of associated disorders, such as chronic obstructive pulmonary disorder, pulmonary fibrosis, and HIV or AIDS.
The diagnosis of non-small cell lung cancer is done with the help of laboratory tests and chest X-rays. CT scans, biopsy, and sputum cytology are the confirmatory diagnostic measures used to analyse the anatomy of the lungs and other respiratory organs. Bronchoscopy and thoracoscopy are the procedures used to examine the airways and chest.
The non-small cell lung cancer consists of several stages, depending on the spreading of the cancerous cells. The treatment strategies are incorporated based on the different stages- stage 0, stage I, stage II, stage III, and stage IV. NSCLC accounts for nearly 85 per cent of all lung cancers prevalent across the world.
The non-small cell lung cancer treatment market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Drug Class
Market Breakup by Therapy Type
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing prevalence of non-small cell lung cancer has been driving the market growth. NSCLC accounts for 80-85 per cent of all the prevalent lung cancer cases globally. This can be attributed to the increased demand for the non-small cell lung cancer treatment market.
The growing demand for diagnostics and therapeutics has stimulated the focus of big pharmaceutical companies towards constant research and innovation for advanced treatment care, bolstering the efficacy of the existing therapeutics. The rising investments by the key players in the research and development activities and favouring government initiatives are anticipated to fuel the market growth further.
The market growth can further be accelerated by the increasing number of diagnoses and improving healthcare-related awareness. The entry of advanced and novel therapeutic interventions is also expected to aid the expansion of the non-small cell lung cancer treatment market. The introduction of targeted therapies and sophisticated treatment facilities has led to significant advancements in healthcare.
North America is anticipated to dominate the regional markets owing to the increase in the patient pool, a growing number of chain smokers, and the existence of advanced immunotherapies. Europe is also expected to hold a significant share in the non-small cell lung cancer treatment market because of the rising adoption of advanced therapeutics and improved awareness.
The treatment of non-small cell lung cancer treatment is dependent on the extent of distribution of cancerous cells. There are different treatment regimens based on the stage of cancer and the affected areas of the body. Surgery is the first-line treatment for most of the diagnosed cases. In these procedures, the tumour is removed, including the surrounding healthy tissue around that tumour.
Radiofrequency ablation and radiation therapy are also used for surgery-intolerant patients. In radiofrequency ablation, the surgeon eradicates the cancerous cells by heating the tumour with high-energy radio waves. Radiation therapy is based on the killing of cancerous cells with the help of powerful X-ray beams.
Chemotherapy is the most commonly used procedure for the management of non-small cell lung cancer. This therapy adheres to the further growth of the cancerous cells and hence, stops the further spread of cancer. Chemotherapy can be given through oral and intravenous routes.
With extensive research, targeted drug therapies have been discovered and have improved therapeutic effects. The targeted drug therapies act by specific targeting abnormal cells without hampering the healthy cells. The two commonly used targeted therapies are tyrosine inhibitors and monoclonal antibodies.
Immunotherapy is another therapeutic procedure based on the application of certain drugs to boost the strength of the immunity system. This assists the immune system to identify its healthy cells and cancerous cells. The drugs used in immunotherapy are called checkpoint inhibitors and include atezolizumab, pembrolizumab, and cemiplimab. The increased demand for these targeted immunotherapies has attributed to the growth of the non-small cell lung cancer treatment market growth during the forecast period.
The recent discovery of novel targeted therapies has been of major interest to experts, researchers, and key players. Tremendous efforts and intensive research and development are under process for immunotherapy and tyrosine kinase inhibitors. Despite the discovery of many novel oncological agents, the focus of the scientists is to explore the optimisation of new therapeutic interventions into clinical practice.
AstraZeneca, a key market trial, has funded the clinical trials of the novel drug, Osimertinib. The ongoing ADAURA trials for this drug have shown some promising effects for the treatment of early-stage EGFRm non-small cell lung cancer. The drug has also reduced the chances of disease recurrence in patients during clinical studies.
Sapanisertib, an investigational drug, discovered by Calithera Biosciences has been granted fast-track approval by the FDA for the treatment of non-small cell lung cancer. This drug is specifically approved for the treatment of the mutated nuclear erythroid 2-related factor tumours and is still under further investigation. This type of mutation is prevalent in around 15 per cent of the patients suffering from metastatic squamous non-small cell lung cancer.
GlaxoSmithKline, a major company, is performing Phase III clinical trials for the Jemperli drug. This drug has shown positive effects in the phase II trials, and henceforth, progressed to the advanced stages for further assessment.
Recently, FDA has given fast-track approval to the combination therapy of Pembrolizumab and Eftilagimod Alpha for the treatment of the first line of non-small cell lung cancer. This will stimulate the therapeutic prospects in the field of immunotherapy and will provide more effective and durable solutions to the patients.
The significant advancements have led to the discovery of many novel therapeutic products, once approved, these drugs are anticipated to bolster the non-small cell lung cancer treatment market growth and development.
The report gives an in-depth analysis of the key players involved in the non-small cell lung cancer treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Treatment Type||
|Breakup by Drug Class||
|Breakup by Therapy Type||
|Breakup by Distribution Channel||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Non-Small Cell Lung Cancer Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Non-Small Cell Lung Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.3 Europe Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.5 Latin America Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Non-Small Cell Lung Cancer Epidemiology (2016-2031)
6 Global Non-Small Cell Lung Cancer Treatment Market Overview
6.1 Global Non-Small Cell Lung Cancer Treatment Market Historical Value (2016-2022)
6.2 Global Non-Small Cell Lung Cancer Treatment Market Forecast Value (2023-2031)
7 Global Non-Small Cell Lung Cancer Treatment Market Landscape
7.1 Non-Small Cell Lung Cancer: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Non-Small Cell Lung Cancer: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Drug Class
7.2.4 Analysis by Therapy Type
7.2.5 Analysis by Distribution Channel
7.2.6 Analysis by End User
8 Non-Small Cell Lung Cancer : Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Non-Small Cell Lung Cancer Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Non-Small Cell Lung Cancer Treatment Market Segmentation
11.1 Global Non-Small Cell Lung Cancer Treatment Market by Type
11.1.1 Market Overview
11.1.3 Squamous Cell Carcinoma
11.1.4 Large Cell Carcinoma
11.2 Global Non-Small Cell Lung Cancer Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.4 Radiation Therapy
11.2.5 Targeted Therapy
11.3 Global Non-Small Cell Lung Cancer Treatment Market by Drug Class
11.3.1 Market Overview
11.3.2 Alkylating Agents
11.3.3 Epidermal Growth Factor Receptor Blocker
11.3.5 Mitotic Inhibitors
11.3.6 Multi-kinase Inhibitors
11.4 Global Non-Small Cell Lung Cancer Treatment Market by Therapy Type
11.4.1 Market Overview
11.4.2 Single Drug Therapy
11.4.3 Combination Therapy
11.5 Global Non-Small Cell Lung Cancer Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.6 Global Non-Small Cell Lung Cancer Treatment Market by End User
11.6.1 Market Overview
11.6.4 Specialty Clinics
11.7 Global Non-Small Cell Lung Cancer Treatment Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Non-Small Cell Lung Cancer Treatment Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Non-Small Cell Lung Cancer Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Non-Small Cell Lung Cancer Treatment Market
14.1 Market Share by Country
15 Latin America Non-Small Cell Lung Cancer Treatment Market
15.1 Market Share by Country
16 Middle East and Africa Non-Small Cell Lung Cancer Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc. (F. Hoffmann-La Roche Ltd)
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Celgene Corporation (Bristol-Myers Squibb Company)
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Astellas Pharma Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Boehringer Ingelheim International GmbH
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 Takeda Pharmaceutical Company Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.12 Clovis Oncology
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.13 Johnson & Johnson Services, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.14 Teva Pharmaceutical Industries Ltd.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
24 Non-Small Cell Lung Cancer Treatment - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 17.62 billion in 2022, driven growing demand for diagnostics and therapeutics.
The market is likely to grow at a rate of 10.00% during the forecast period of 2023-2031 to reach a value of nearly USD 41.97 billion by 2031.
The market growth is primarily driven by the rising cases of lung cancer, the growing number of chain smokers, the rising adoption of advanced healthcare, and increasing research and developmental activities.
The major types of non-small cell lung cancer include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, among others.
The treatment types used in the market include immunotherapy, chemotherapy, radiation therapy, and targeted therapy, among others.
The drug classes used in treatment include alkylating agents, epidermal growth factor receptor blocker, antimetabolites, mitotic inhibitors, and multi-kinase inhibitors, among others.
The therapy types can be divided into single drug therapy and combination therapy.
The distribution channels used in the treatment market include hospital pharmacies, retail pharmacies, and online channels, among others.
The end-user segments can be divided into hospitals, homecare, and specialty clinics, among others.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America is anticipated to hold the largest share of the during the forecast period.
The key companies involved in the market are Genentech, Inc. (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation (Bristol-Myers Squibb Company), Pfizer Inc., AstraZeneca, Sanofi, Novartis AG, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Clovis Oncology, Johnson & Johnson Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.